Seres Therapeutics Analyst Ratings
Seres Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/03/2023 | -14.31% | Goldman Sachs | $4 → $1.25 | Maintains | Sell |
06/26/2023 | 722.65% | Oppenheimer | → $12 | Assumes | → Outperform |
04/28/2023 | 585.54% | Chardan Capital | $12 → $10 | Maintains | Buy |
04/21/2023 | 379.88% | JP Morgan | → $7 | Initiates Coverage On | → Neutral |
03/21/2023 | 928.31% | Canaccord Genuity | $11 → $15 | Maintains | Buy |
03/08/2023 | 654.1% | Canaccord Genuity | $17 → $11 | Maintains | Buy |
03/08/2023 | 722.65% | Chardan Capital | → $12 | Reiterates | → Buy |
03/08/2023 | 1613.85% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
02/08/2023 | 1613.85% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
09/07/2022 | 516.99% | Piper Sandler | $7 → $9 | Maintains | Overweight |
05/23/2022 | 379.88% | Piper Sandler | $32 → $7 | Maintains | Overweight |
07/23/2021 | 1888.07% | Canaccord Genuity | $42 → $29 | Maintains | Buy |
07/23/2021 | 996.87% | Chardan Capital | $30 → $16 | Maintains | Buy |
07/23/2021 | 1133.98% | Oppenheimer | $36 → $18 | Maintains | Outperform |
07/23/2021 | 1613.85% | HC Wainwright & Co. | $46 → $25 | Maintains | Buy |
07/23/2021 | 379.88% | Goldman Sachs | $24 → $7 | Downgrades | Neutral → Sell |
05/05/2021 | 3053.49% | HC Wainwright & Co. | $41 → $46 | Maintains | Buy |
03/05/2021 | 1956.63% | Chardan Capital | $27.5 → $30 | Upgrades | Neutral → Buy |
12/23/2020 | — | JMP Securities | Initiates Coverage On | → Market Perform | |
09/21/2020 | 2779.28% | Canaccord Genuity | $38 → $42 | Maintains | Buy |
09/18/2020 | 1785.24% | Chardan Capital | → $27.5 | Downgrades | Buy → Neutral |
08/18/2020 | 2642.17% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
08/11/2020 | 2710.72% | HC Wainwright & Co. | $8 → $41 | Maintains | Buy |
08/11/2020 | 1888.07% | Jefferies | $4 → $29 | Upgrades | Hold → Buy |
08/11/2020 | 2128.01% | Chardan Capital | $12.5 → $32.5 | Maintains | Buy |
03/31/2020 | 379.88% | Oppenheimer | $8 → $7 | Maintains | Outperform |
04/30/2019 | 379.88% | Jefferies | → $7 | Initiates Coverage On | → Hold |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/03/2023 | -14.31% | 高盛 | 4 美元 → 1.25 美元 | 維護 | 賣出 |
06/26/2023 | 722.65% | 奧本海默 | → 12 美元 | 假設 | → 跑贏大盤 |
04/28/2023 | 585.54% | 查丹資本 | 12 美元 → 10 美元 | 維護 | 買 |
04/21/2023 | 379.88% | 摩根大通 | → 7 美元 | 啓動覆蓋範圍開啓 | → 中立 |
03/21/2023 | 928.31% | Canaccord Genu | 11 美元 → 15 美元 | 維護 | 買 |
03/08/2023 | 654.1% | Canaccord Genu | 17 美元 → 11 美元 | 維護 | 買 |
03/08/2023 | 722.65% | 查丹資本 | → 12 美元 | 重申 | → 購買 |
03/08/2023 | 1613.85% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
02/08/2023 | 1613.85% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
09/07/2022 | 516.99% | 派珀·桑德勒 | 7 美元 → 9 美元 | 維護 | 超重 |
05/23/2022 | 379.88% | 派珀·桑德勒 | 32 美元 → 7 美元 | 維護 | 超重 |
2021 年 7 月 23 日 | 1888.07% | Canaccord Genu | 42 美元 → 29 美元 | 維護 | 買 |
2021 年 7 月 23 日 | 996.87% | 查丹資本 | 30 美元 → 16 美元 | 維護 | 買 |
2021 年 7 月 23 日 | 1133.98% | 奧本海默 | 36 美元 → 18 美元 | 維護 | 跑贏大盤 |
2021 年 7 月 23 日 | 1613.85% | HC Wainwright & Co. | 46 美元 → 25 美元 | 維護 | 買 |
2021 年 7 月 23 日 | 379.88% | 高盛 | 24 美元 → 7 美元 | 降級 | 中性 → 賣出 |
2021 年 5 月 5 日 | 3053.49% | HC Wainwright & Co. | 41 美元 → 46 美元 | 維護 | 買 |
03/05/2021 | 1956.63% | 查丹資本 | 27.5 美元 → 30 美元 | 升級 | 中性 → 買入 |
12/23/2020 | — | JMP 證券 | 啓動覆蓋範圍開啓 | → 市場表現 | |
2020 年 9 月 21 日 | 2779.28% | Canaccord Genu | 38 美元 → 42 美元 | 維護 | 買 |
09/18/2020 | 1785.24% | 查丹資本 | → 27.5 美元 | 降級 | 買入 → 中性 |
08/18/2020 | 2642.17% | 派珀·桑德勒 | → 40 美元 | 啓動覆蓋範圍開啓 | → 超重 |
08/11/2020 | 2710.72% | HC Wainwright & Co. | 8 美元 → 41 美元 | 維護 | 買 |
08/11/2020 | 1888.07% | 傑富瑞集團 | 4 美元 → 29 美元 | 升級 | 持有 → 買入 |
08/11/2020 | 2128.01% | 查丹資本 | 12.5 美元 → 32.5 美元 | 維護 | 買 |
2020 年 3 月 31 日 | 379.88% | 奧本海默 | 8 美元 → 7 美元 | 維護 | 跑贏大盤 |
2019 年 4 月 30 日 | 379.88% | 傑富瑞集團 | → 7 美元 | 啓動覆蓋範圍開啓 | → 按住 |
What is the target price for Seres Therapeutics (MCRB)?
Seres Therapeutics(MCRB)的目標價格是多少?
The latest price target for Seres Therapeutics (NASDAQ: MCRB) was reported by Goldman Sachs on November 3, 2023. The analyst firm set a price target for $1.25 expecting MCRB to fall to within 12 months (a possible -14.31% downside). 9 analyst firms have reported ratings in the last year.
高盛於2023年11月3日公佈了Seres Therapeutics(納斯達克股票代碼:MCRB)的最新目標股價。該分析公司將目標股價定爲1.25美元,預計MCRB將在12個月內降至12個月內(可能下跌-14.31%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Seres Therapeutics (MCRB)?
分析師對Seres Therapeutics(MCRB)的最新評級是多少?
The latest analyst rating for Seres Therapeutics (NASDAQ: MCRB) was provided by Goldman Sachs, and Seres Therapeutics maintained their sell rating.
Seres Therapeutics(納斯達克股票代碼:MCRB)的最新分析師評級由高盛提供,Seres Therapeutics維持其賣出評級。
When is the next analyst rating going to be posted or updated for Seres Therapeutics (MCRB)?
Seres Therapeutics(MCRB)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seres Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seres Therapeutics was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Seres Therapeutics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Seres Therapeutics的最新評級是在2023年11月3日公佈的,因此您應該預計下一個評級將在2024年11月3日左右公佈。
Is the Analyst Rating Seres Therapeutics (MCRB) correct?
分析師對Seres Therapeutics(MCRB)的評級是否正確?
While ratings are subjective and will change, the latest Seres Therapeutics (MCRB) rating was a maintained with a price target of $4.00 to $1.25. The current price Seres Therapeutics (MCRB) is trading at is $1.46, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Seres Therapeutics(MCRB)評級維持不變,目標股價爲4.00美元至1.25美元。Seres Therapeutics(MCRB)目前的交易價格爲1.46美元,超出了分析師的預期區間。